Avida Biomed

What Avida Biomed does

Avida Biomed Inc. is a biotechnology company, founded in 2019 and based in Fremont, California, that develops target enrichment workflows and methylation sequencing (Methyl-Seq) reagent chemistries for next-generation sequencing (NGS) applications. The company's core products are the Avida Methyl Reagent Kit, a high-sensitivity targeted methyl-seq kit capable of working from as little as 3 ng of input DNA, and the Avida Duo Methyl Reagent Kit, which combines DNA variant detection and methylation alteration analysis in a single multiomic workflow. These kits are designed to address the technical demands of liquid biopsy analysis, multi-omics studies, and low-input oncology samples, where sensitivity and reproducibility are critical.

The company serves primarily oncology researchers conducting translational and clinical-adjacent research, with a vertical segmentation approach focused on high-sensitivity NGS applications. Prior to its acquisition, Avida was a sub-10-person private company; the founders include Shengrong Lin (Founder and CEO) and Grace Zhao (Co-Founder, Head of Clinical Research). Revenue figures, pricing, and customer counts were never publicly disclosed.

In January 2023, Avida Biomed was acquired by Agilent Technologies Inc. for $30 million as a strategic tuck-in to strengthen Agilent's NGS Library Prep and Target Enrichment Reagents portfolio. Following the acquisition, the Avida-branded reagent kits are sold through Agilent's global direct sales force, e-commerce platform, and authorized distribution channels, giving the products worldwide reach that would not have been achievable as an independent startup. The product line now sits within Agilent's broader life sciences division, and standalone revenue mechanics for Avida as a separate entity are no longer reported.

Name

Avida Biomed

Legal name

Avida Biomed Inc.

Website

https://avidabio.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

1–10 employees

Short description

Avida Biomed is a Fremont, California-based biotechnology company that develops target enrichment and methylation sequencing reagent kits for next-generation sequencing, serving oncology researchers conducting liquid biopsy, multi-omics, and low-input sample workflows. Acquired by Agilent Technologies in January 2023.

Ownership category

akta.pro rank

Product category

NGS Library Prep & Methylation Sequencing Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• NGS library prep reagents
• Methylation sequencing kits
• Target enrichment workflows
• Multiomic analysis reagents
• Low-input DNA reagents

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

Avida Biomed develops and manufactures target enrichment and methylation sequencing (Methyl-Seq) reagent kits for next-generation sequencing (NGS) workflows. Its products support high-sensitivity applications such as liquid biopsy, multi-omics analysis, and low-input sample processing, primarily for oncology research. Since its January 2023 acquisition by Agilent Technologies, the kits are marketed under the Avida brand through Agilent's life sciences portfolio.

Product overview

Avida Biomed is a provider of target enrichment and methylation sequencing reagents for next-generation sequencing (NGS) applications. Following its acquisition by Agilent Technologies in January 2023 for $30 million, Avida's product portfolio has been integrated into Agilent's NGS Library Prep & Target Enrichment Reagents division. The portfolio consists of methylation sequencing reagent kits including the Avida Duo Methyl Reagent Kit (for multiomic analysis combining DNA variants and methylation alteration detection) and the Avida Methyl Reagent Kit (for high-sensitivity targeted methyl-seq starting from as low as 3 ng). These reagents are designed to support high sensitivity applications such as liquid biopsy, multi-omics analysis, and low input samples for oncology research.

Differentiator

Problem solved

Functional benefit

Brands

• Avida Duo Methyl Reagent Kit: Multiomic analysis combining DNA variants and methylation alteration detection in next-generation sequencing workflows.
• Avida Methyl Reagent Kit

Products and services

• Avida Duo Methyl Reagent Kit Multiomic analysis reagent kit that combines DNA variant detection and methylation alteration detection in a single NGS workflow, intended for oncology researchers performing liquid biopsy and multi-omics studies.
• Avida Methyl Reagent Kit High-sensitivity targeted methyl-seq reagent kit capable of working from as low as 3 ng of input DNA, powered by advanced target enrichment chemistry for DNA methylation analysis in research and low-input samples.

Quantifiable outcome

• High-sensitivity targeted methyl-seq starting from as low as 3 ng input

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• New England Biolabs (NEB): NEBNext is NEB's NGS library prep and target enrichment reagent line, directly competing with Avida's Methyl-Seq kits in workflow chemistry for next-generation sequencing. Both serve genomics researchers with reagent kits that target similar methylation and library prep applications.
• Zymo Research: Zymo Research is a leading provider of DNA methylation and bisulfite conversion reagents, with products like the EZ DNA Methylation and Pico Methyl-Seq kits that compete directly with Avida's targeted methylation sequencing kits. Strong overlap in methylation-focused NGS workflows for epigenetics and oncology research.
• Qiagen: Qiagen's QIAseq NGS target enrichment and DNA methylation product lines compete head-on with Avida's methylation sequencing reagents, serving translational research and clinical genomics customers with similar library prep and methyl-seq chemistries.
• Diagenode: Diagenode specializes in methylation and epigenetics sample preparation kits, including bisulfite conversion and methyl-seq workflows for low-input samples. Highly comparable to Avida's high-sensitivity, low-input methylation sequencing reagent portfolio.
• Twist Bioscience: Twist Bioscience offers NGS target enrichment through custom and catalog capture panels, plus methylation tools, competing with Avida in the targeted sequencing reagent market. Both companies emphasize workflow flexibility and customizability for translational genomics customers.

Broad incumbents

• Roche (KAPA Biosystems): Roche's KAPA NGS library prep and target enrichment portfolio competes broadly with Avida's Methyl-Seq kits. As a major life sciences tools provider with much larger scale, Roche is a broad incumbent in the same NGS reagent space.
• Illumina: Illumina is the dominant NGS platform and instruments provider with an expanding portfolio of library prep and methylation reagents (e.g., Illumina DNA Prep with Enrichment, TruSeq Methyl). Comparable as a broad incumbent offering overlapping methylation and NGS reagent chemistries.
• PerkinElmer: PerkinElmer operates across life science reagents, genomics, and diagnostics, with offerings in methylation analysis and NGS sample prep that overlap with Avida's Methyl-Seq reagent kits as part of a broader life sciences portfolio.
• Bio-Rad Laboratories: Bio-Rad provides life science research reagents and instruments, including products serving genomics and molecular biology research workflows. Comparable as a broad life sciences tools incumbent with overlapping customer base in academic and translational research.
• Beckman Coulter Life Sciences (Danaher): Beckman Coulter Life Sciences, part of Danaher, offers nucleic acid extraction and library prep automation that overlaps with NGS reagent workflows used in methylation sequencing. Comparable as a broad life sciences tools and automation incumbent.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avida Biomed